



## Report for the second quarter of 2020


### April – June in brief

- **Net sales** rose by 35 percent to SEK 15,490 (11,509) thousand. Adjusted for acquired sales, growth rose by 11% to SEK 12,714 thousand.
- **Gross profit/loss** improved by SEK 978 thousand and totaled SEK 13,146 (12,168) thousand.
- **Operating result before depreciation and amortization (EBITDA)** totaled SEK -38 (2,390) thousand and was negatively impacted by non-recurring items for acquisitions and restructuring costs of SEK 1 million.
- **Operating result** totaled SEK -1,291 (1,628) thousand.
- **Comprehensive income for the period** totaled SEK -3,124 (1,380) thousand.
- **Comprehensive income per share**, basic and diluted, totaled SEK -0.05 (0.02).
- **Cash flow from operating activities** was SEK -123 (profit: 145) thousand.
- **Cash and cash equivalents at the end of the period** totaled SEK 46,554 (8,921) thousand.
- Genovis has acquired all shares of QED Bioscience Inc. Total cost of the acquisition, including transaction costs, is SEK 20 million QED merged with Genovis Inc.
- The Annual General Meeting, held on May 5, 2020, elected Torben Jørgensen to serve as chairman of the Board of Directors and reelected Board members Kenth Petersson, Mikael Lönn and Lotta Ljungqvist.

### January – June in brief

- **Net sales** rose by 15 percent to SEK 26,965 (23,440) thousand. Adjusted for bioprocess sales in 2019 and acquired sales, sales growth totaled 15%.
- **Gross profit** totaled SEK 24,123 (23,309) thousand.
- **Operating result before depreciation and amortization (EBITDA)** totaled SEK -885 (profit 5,086) thousand and was negatively impacted by non-recurring items for acquisitions and restructuring of SEK 2.3 million.
- **Operating result** totaled SEK -3,180 (profit: 3,571) thousand.
- **Comprehensive income for the six-month period** totaled SEK -5,038 (2,971) thousand
- **Comprehensive income per share**, basic and diluted, totaled SEK -0.08 (0.05).

### Sales by quarter 2017 - 2020



## Comments from Fredrik Olsson, Chief Executive Officer

The coronavirus pandemic has affected society at large during the quarter, and our business operations were no exception. The pandemic has been accompanied by several unforeseen challenges that have caused us to reset and focus our resources on new circumstances. I am proud that despite these challenges, our sales continued to grow by 35% and, excluding acquired sales, we were able to achieve sales growth of 11%, given the market situation in the second quarter.

The beginning of the quarter was clearly affected by the restrictions implemented in several key markets in Europe and North America, resulting in a pronounced decline in customer activity. As more markets eased the restrictions, we saw a gradual increase in activity in May and June. In the Asian markets we've seen a clear recovery after a weak first quarter caused by the pandemic.

In addition to the loss of sales, the operating result was also affected by non-recurring acquisition-related costs and increased personnel costs as we added 14 people to the organization, compared with the second quarter last year. Adjusted for the acquisition-related costs, the operating loss for the quarter is SEK 0.3 million.

To date, we have launched two products this year. FabRICATOR™ MagIC, which was launched in June, is intended for simplified and parallel analysis of antibody molecules in automated systems in several parts of our customers' value chains. The product has initially been adapted for an instrument from Thermo Fischer Scientific, associated with our collaboration agreement relating to analysis of biologicals. At the beginning of the current quarter, we launched our second product for the year, GalactEXO™, a new enzyme for glycan analysis of proteins, and we still intend to launch more products during the second half of the year.

During the second quarter, we also closed the deal and acquired QED Bioscience. Despite the challenging market situation, QED's activities in San Diego have achieved sales on a par with the same period the previous year and the company has been fully operational since we formally took over the business on April 29. Given the situation associated with the pandemic, we had to begin the integration process remotely, for which reason we gave top priority to fully integrating QED into our various



business and reporting systems, which has now been concluded. We can now devote our full attention to implementing combined marketing and business strategies as the market situation gradually improves.

We have intentionally chosen to lean forward into a challenging market situation and have focused our efforts and resources on our long-term strategies within automated analysis, glycomics and integration of the newly completed acquisition of QED Bioscience.

Despite these challenges and the uncertain market situation with clear limitations, including canceled marketing activities and customer meetings, which are key cornerstones in our business, my colleagues at Genovis have done an incredible job this quarter. We have also had the opportunity to welcome new employees from QED and we now have about 40 employees worldwide, working on developing and growing the business at Genovis together with our customers.

In the short term, there is still uncertainty about how quickly economies and activities in various locations can recover and how any new waves of the pandemic could affect customer activity. But in the long run, I remain confident in our ability to continue on this growth journey with Genovis through customer-driven innovation in close collaboration with our growing customer base.

## Genovis Group in brief

*Genovis will apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future.*



Genovis' enzymes are in a market that covers the entire life science and biotech supply industry. The Parent Company in Lund handles sales in the European market and the subsidiary, Genovis Inc., handles all sales in the North American market. In Asia Genovis works both with direct sales and with distributors who are familiar with the local market.

Genovis' business model has a long-term and sustainable focus based on two primary strategies that together are the drivers of the Company's success:

- Continue to launch unique new products, thereby expanding the product portfolio for continued growth.
- Deliberately work to encourage customers to use Genovis products in several stages further along on the drug development value chain.

The Company will therefore continue to be creative and develop unique new high-value products for its customers. New products are mainly aimed at customers who work in the discovery phase or in preclinical development. In this phase most of the Company's customers are both curious and willing to test new analytical methods to address the clear needs and challenges related to analyzing biological drugs. More and more of Genovis' customers in the biopharma industry are now using the products farther along in the value chain for biological drug development and have growing confidence in Genovis as a provider of high-quality, innovative products for the biopharma industry. During the year Genovis enzymes were also used for the first time in a clinical project for production of a biological drug candidate. Genovis will continue to launch innovative products as the brand grows stronger and in pace with the expansion and broadening of our customer base.

### The Group's financial performance in summary

(SEK 000s)	Q2		H1		Full year
	2020	2019	2020	2019	2019
Net sales	15,490	11,509	26,965	23,440	60,549
Gross profit	13,146	12,168	24,123	23,309	56,187
Operating profit/loss (EBIT)	-1,291	1,628	-3,180	3,571	10,066
Comprehensive income for the period	-3,124	1,380	-5,038	2,971	9,549
Cash flow from operating activities	-123	145	-1,629	2,855	13,125
Cash and cash equivalents at close of period	46,554	8,921	46,554	8,921	14,992
Earnings per share (kronor)	-0.05	0.02	-0.08	0.05	0.15


## Financial overview

### Net sales

Consolidated net sales for the six-month period totaled SEK 26,965 (23,440) thousand, an increase in sales of about SEK 3.5 million, or 15 percent. Adjusted for currency effects, net sales for the six-month period totaled SEK 26,352 thousand, corresponding to an increase in sales of 12 percent. Adjusted for bioprocess sales, acquired sales and currency effects, net sales totaled SEK 23,576 thousand, an organic growth of about 12 percent.

Consolidated net sales for the second quarter totaled SEK 15,490 (11,509) thousand, an increase in sales of 35 percent. Adjusted for bioprocess sales in 2019, acquired sales and currency effects, organic growth for the quarter was 8.5 percent, or an increase of SEK 975 thousand.

### Sales proceeds, 12 months revolving (2017 – 2020)




### Operating profit/loss before depreciation and amortization (EBITDA)

Operating result before depreciation and amortization for the six-month period was a loss of SEK 885 (profit: 5,086) thousand. Operating result before depreciation and amortization for the second quarter was a loss of SEK 38 (profit: 2,390) thousand.

### Operating profit/loss (EBIT)

Operating result after depreciation and amortization for the six-month period was a loss of SEK 3,180 (profit: 3,571) thousand. Operating result after depreciation and amortization for the quarter was a loss of SEK 1,291 (profit: 1,628) thousand.

## Operating profit/loss (EBIT) rolling 12 months



## Comprehensive income

Comprehensive income for the six-month period was a loss of SEK 5,038 (profit: 2,971) thousand.

Earnings per share, based on

a weighted average of the number of outstanding shares, totaled SEK -0.08 (0.05). Comprehensive income for the quarter was SEK -3,124 (1,380) thousand. Earnings per share, based on a weighted average of the number of outstanding shares, totaled SEK -0.05 (0.02).

## Costs

Consolidated expenses for the six-month period increased by SEK 8,255 thousand to SEK 29,917 (21,662) thousand. The cost of raw materials and consumables increased by SEK 690 thousand to SEK 2,614 (1,924) thousand, while employee benefits expense rose by SEK 3,508 thousand to SEK 13,504 (9,996) thousand as a result of new employees hired and staff added through the acquisition of QED Bioscience. Other external expenses increased by SEK 841 to SEK 9,068 (8,227) thousand. Other operating expenses totaled SEK 2,436 (0) thousand attributable to non-recurring items related to the acquisition and restructuring for SEK 2,330 thousand. Depreciation and amortization during the six-month period increased by SEK 780 thousand to SEK 2,295 (1,515) thousand.

Consolidated expenses for the second quarter amounted to SEK 16,002 (11,377) thousand. Expenses are allocated as follows: raw materials and consumables SEK 1,565 (837) thousand, personnel costs, which increased by SEK 2,189 thousand to 7,403 (5,214) thousand and other external expenses, which increased by SEK 135 thousand to SEK 4,699 (4,564) thousand. Other operating expenses amounted to SEK 1,082 (0) and relate to acquisition and restructuring costs. Depreciation and amortization for the quarter amounted to SEK 1,253 (762) thousand.

## Investments

The Group's net capital expenditure for the six-month period totaled SEK 16,499 (2,434), of which SEK 882 (2,254) is attributable to property, plant, and equipment, primarily laboratory equipment and computers, and SEK 15,618 (180) thousand attributable to investments in intangible assets.

Net capital expenditure for the quarter totaled SEK 15,758 (1,708), of which SEK 487 (1,661) is attributable to property, plant, and equipment, primarily laboratory equipment, and SEK 15,271 (47) thousand relates to investments in intangible assets, of which SEK 14,933 is attributable to goodwill

and intangible assets in customer relationships that arose in conjunction with the acquisition of QED Bioscience. For more information, see the acquisition analysis below.

## Cash flow and financial position

Total shareholders' equity for the Group was SEK 80,151 (29,042) thousand after taking the result for the six-month period into account. Equity per share based on the weighted average of the number of outstanding shares (basic and diluted) at the end of the period was SEK 1.22 (0.46). The Group's equity ratio at the end of the six-month period was 81 (68) percent.

Consolidated cash and cash equivalents at the end of the six-month period amounted to SEK 46,554 (8,921) thousand. Taking expected revenue into account, the Board believes that the existing working capital is sufficient to run the Company over the next twelve months.

Consolidated cash flow for the six-month period was SEK 31,562 (-660) thousand. Cash flow from financing activities totaled SEK 49,690 (1,081) thousand. Consolidated cash flow for the quarter was SEK -15,087 (-2,103) thousand. Cash flow from financing activities totaled SEK 794 (-540) thousand.

Only the Group has interest-bearing liabilities, where liabilities to credit institutions relate in their entirety to the present value of estimated future lease payments, which also includes rent for premises.

### Liabilities to credit institutions (SEK 000s)

#### Noncurrent interest-bearing liabilities

Maturity between 1 and 4 years	3,396
--------------------------------	-------

#### Current interest-bearing liabilities

Maturity within 1 year	1,639
------------------------	-------

## Taxes

The Group has a deferred tax asset that arises from the Parent Company, amounting to SEK 1,718 (1,718) thousand at the end of the period. The Board believes that future taxable surpluses will be available against which the unutilized tax losses can be utilized.

## Employees

On June 30, 2020, the Group employed 35 people, an increase of 14 employees compared with the same period the previous year, when the Group had 21 employees. In all, 26 people are employed by the Parent Company in Lund and nine people work for the subsidiary Genovis Inc. in the US.

## Share capital and share performance

Share capital at the end of the quarter was SEK 16,366,000 and the total number of shares was 65,465,714 with a par value of SEK 0.25. Genovis' shares are traded on Nasdaq First North Stockholm under the ticker symbol GENO. First North is Nasdaq's European emerging market intended for small, growing businesses, with a less extensive rulebook than the main market.

## Parent Company

Net sales and operating profit/loss in the Parent Company are attributable to the primary and only business area: product sales of products and/or of research-based innovations. According to Genovis, the Company does not meet the definition of geographical areas under IFRS 8 and therefore no secondary segment information is provided.

### Revenue

Revenue for the six-month period, including change in inventory finished goods, totaled SEK 19,189 (19,278) thousand, including SEK 19,417 (17,484) thousand attributable to sales and SEK 583 (389) thousand attributable to other revenue. Revenue for the quarter, including change in inventory finished goods, totaled SEK 9,577 (10,210) thousand, including SEK 10,356 (8,714) thousand attributable to sales and SEK 32 (99) thousand attributable to other revenue. Other revenue relates to foreign exchange gains.

### Costs

The Parent Company's operating expenses for the six-month period totaled SEK 20,909 (17,317) thousand and expenses for the second quarter totaled SEK 9,192 (9,184) thousand.

### Performance

Net loss was SEK 1,936 (profit: 1,961) thousand for the six-month period, while net profit was SEK 170 (1,025) thousand for the second quarter.

### Investments

Consolidated capital expenditure for the six-month period totaled SEK 21,144 (2,434) thousand, of which SEK 467 (180) is attributable to property, plant, and equipment (mainly laboratory equipment and computers). Investments in intangible assets totaled SEK 20,495 (2,254) thousand, of which SEK 685 thousand relates to patents and SEK 19,992 thousand relates to shares acquired in QED Bioscience.

For the second quarter, capital expenditure amounts to SEK 20,402 (1,708) thousand, including SEK 72 (1,661) thousand attributable to property, plant, and equipment and SEK 20,330 (47) attributable to intangible assets.

### Taxes

The Parent Company has a deferred tax asset and at the end of the quarter it was SEK 1,718 (1,718) thousand, corresponding to a loss carryforward of SEK 8,028 thousand. The Board believes that future taxable surpluses will be available against which the unutilized tax losses can be utilized. The Company's total tax loss amounts to SEK 171 million (169).

## Subsidiary Genovis Inc.

The subsidiary Genovis Inc. handles all sales in the North American market.

## Business combination - QED Bioscience Inc.

On April 29, 2020, Genovis acquired all shares in the privately held company QED Bioscience Inc. (QED), based in San Diego, California, USA. The total purchase price was SEK 18,164 thousand, of which SEK 15,899 thousand was paid in cash at the time of possession and a deferred purchase consideration of SEK 2,265 thousand will be paid in April 2021. Including transaction costs of SEK 1,828 thousand, the total cost of the acquisition is SEK 20 million. The acquired entity had annual sales in 2019 totaling SEK 17,733 (16,289) thousand and net profit of SEK 2,190 (591) thousand. The acquisition provides Genovis with a well-established supplier of high-quality antibodies that will facilitate synergies and business development opportunities together with Genovis' platform technology for antibody labeling, GlyCLICK®, as well as a relevant customer base for the companies' shared technologies and offerings.

The acquisition of QED entails the acquisition of net assets totaling SEK 13,571 thousand, including customer relationships of SEK 11,423 thousand. The remainder of the total purchase consideration, amounting to SEK 18,164 thousand, relates to goodwill of SEK 4,592 thousand. Goodwill relates to expected synergistic effects arising from the consolidation of existing operations within development and distribution. The goodwill that arises will not be tax-deductible.

The table below summarizes the purchase consideration for QED Bioscience, as well as the fair value of acquired assets and liabilities recognized on the day of the acquisition.

### Business combination QED Bioscience Inc. (SEK 000s)

Cash paid on the acquisition date	15,899
Deferred purchase consideration	2,265
<b>Total purchase consideration</b>	<b>18,164</b>
<b>Acquired assets and liabilities</b>	
Cash and cash equivalents	1,952
Intangible assets: customer relationships	11,423
Property, plant and equipment	200
Financial assets, incl. IFRS 16	1,979
Inventories	890
Accounts receivable and other receivables	2,846
Deferred tax liability	-3,196
Financial liability, incl. IFRS16	-1,979
Accounts payable and other payables	-544
<b>Total identifiable net assets</b>	<b>13,571</b>
Goodwill	4,592
<b>Total acquired net assets</b>	<b>18,164</b>
Purchase consideration settled in cash	-15,899
Cash and cash equivalents in acquired subsidiaries	1,952
<b>Change in the Group's cash and cash equivalents at acquisition</b>	<b>-13,947</b>

Participations in subsidiaries are recognized as financial assets in the Parent Company. Participations in subsidiaries are recognized at cost less any impairments. Cost includes the purchase consideration paid for the shares and the acquisition costs.

## Other information

### Related party transactions

Genovis' board member and principal owner Mikael Lönn, who holds a 15.26 percent stake in Genovis, owns 12.24 percent of the shares in Redeye AB, for which Mikael Lönn is also a board member. Genovis has purchased analysis services from Redeye AB for a total of SEK 210 thousand during the period.

### Significant events after the end of the reporting period

No other significant events were reported after the end of the period.

### Outlook

Although the Life Science field is relatively independent of business cycles, periods of uncertainty can influence our customers' appetite to invest in new technology. With the majority of the development projects proceeding according to plan, Genovis is positioned to make additional advances with respect to both new products and sales.

The COVID-19 outbreak during the first quarter of 2020 has had a significant impact on the current business climate. Because of the uncertainties related to the future economic effects of the COVID-19 outbreak, senior management cannot assess the short- or long-term impact on the company more precisely at this time.

### Risk Factors

Genovis' general view of the financial risks that could affect operations has not changed since the description published in the most recent annual report. Genovis' business risks include the risk that anticipated revenue might not materialize since the Company is active in a market in which competing companies have substantially larger financial resources at their disposal. For a detailed overview of the Company's financial risks, please refer to page 56 in Genovis' 2019 Annual Report.

### Auditor's review

This report has not been reviewed by the Company's auditor.

### Future reporting dates

Interim report	January 1 - September 30	2020	November 5, 2020
Year-end Report	January 1 – December 31,	2020	February 11, 2021
Interim Report	January 1 – March 31,	2021	April 29, 2021
Half-Yearly Report	January 1 – June 30,	2021	August 12, 2021

Reports may be downloaded at the Genovis website:

<https://investor.genovis.com/sv/finansiella-rapporter/#delarsrapporter>

or requested from the company by phone or letter: Genovis AB, Box 790  
SE-220 07 Lund, Sweden T: +46 (0)46-10 12 30

## **Certified Adviser**

Erik Penser Bank, +46 (0)8 463 83 00, certifiedadviser@penser.se, is the company's certified adviser.

## **Forward-looking information**

This report contains forward-looking information based on the current expectations of Group management at Genovis. Although the management believes that the expectations reflected in such forward-looking information are reasonable, no assurance can be given that such expectations will prove correct. Consequently, actual future results may vary materially from those implied in the forward-looking statements due to such changes in economic, market and competitive conditions, changes in the regulatory environment and other government actions, fluctuations in exchange rates and other factors.

## **Accounting policies**

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the relevant provisions of the Swedish Annual Accounts Act. The report for the Parent Company has been prepared in accordance with chapter 9 of the Swedish Annual Accounts Act, Interim Reports. The accounting policies applied for the Group and the Parent Company are consistent with the accounting policies used in the preparation of the most recent annual report.

## **For more information**

Additional information about the company is available on the company's website: [genovis.com](http://genovis.com)  
For questions about this report, please contact: Fredrik Olsson, CEO, and President, t:  
+46 (0)46-10 12 33.

## Financial information - Group

### Statement of comprehensive income

(SEK 000s)	Q2		H1		Full year
	2020	2019	2020	2019	2019
Net sales	15,490	11,509	26,965	23,440	60,549
Change in inventory, finished goods	-811	1,397	-807	1,405	2,417
Other operating income/expenses*	32	99	579	388	53
Raw materials and consumables	-1,565	-837	-2,614	-1,924	-6,832
<b>Gross profit</b>	<b>13,146</b>	<b>12,168</b>	<b>24,123</b>	<b>23,309</b>	<b>56,187</b>
Personnel costs	-7,403	-5,214	-13,504	-9,996	-22,081
Other external expenses	-4,699	-4,564	-9,068	-8,227	-16,996
Other operating expenses	-1,082	0	-2,436	0	-3,547
<b>Operating profit/loss before depreciation and amortization (EBITDA)</b>	<b>-38</b>	<b>2,390</b>	<b>-885</b>	<b>5,086</b>	<b>13,563</b>
Depreciation, amortization and impairment of plant, property, and equipment and intangible assets	-1,253	-762	-2,295	-1,515	-3,497
<b>Operating profit/loss (EBIT)</b>	<b>-1,291</b>	<b>1,628</b>	<b>-3,180</b>	<b>3,571</b>	<b>10,066</b>
Net financial items	-286	-110	-358	-220	-399
<b>Profit/loss after financial items</b>	<b>-1,577</b>	<b>1,518</b>	<b>-3,538</b>	<b>3,351</b>	<b>9,667</b>
Taxes	54	-165	10	-433	-116
<b>Profit/loss after tax for the period</b>	<b>-1,523</b>	<b>1,353</b>	<b>-3,528</b>	<b>2,918</b>	<b>9,551</b>
<b>Items that may be reclassified subsequently to profit or loss</b>					
Translation of foreign subsidiary	-1,601	27	-1,510	53	-2
<b>Comprehensive income for the period</b>	<b>-3,123</b>	<b>1,380</b>	<b>-5,038</b>	<b>2,971</b>	<b>9,549</b>

\* The item Other operating income/expenses relates to exchange rate gains.

The entire profit is attributable to Parent Company shareholders

	Q2		H1		Full year
	2020	2019	2020	2019	2019
Earnings per share (SEK)*	-0.02	0.02	-0.05	0.05	0.15
<b>Number of shares</b>					
Weighted average for the period	65,465,714	63,100,000	64,724,802	63,100,000	63,100,000
Number of shares at beginning of period	65,465,714	63,100,000	63,100,000	63,100,000	63,100,000
Number of shares at end of period	65,465,714	63,100,000	65,465,714	63,100,000	63,100,000
Share price at end of period, SEK	28.95	19.70	28.95	19.70	25.00

\* Based on weighted average of the number of outstanding shares (basic and diluted)

## Summary Balance Sheet

(SEK 000s)	<u>June 30</u> 2020	<u>June 30</u> 2019	<u>Dec. 31</u> 2019
<b>Assets</b>			
<i>Noncurrent assets</i>			
Intangible assets	18,321	2,611	3,218
Property, plant and equipment	10,181	7,268	9,470
Financial assets	1,798	1,718	1,718
<i>Current assets</i>			
Cash and cash equivalents	21,987	22,274	19,645
	46,554	8,921	14,992
<b>Total assets</b>	<b>98,841</b>	<b>42,792</b>	<b>49,043</b>
<b>Equity and liabilities</b>			
Equity	80,151	29,042	35,620
Noncurrent liabilities	6,357	2,940	2,134
Current liabilities	12,333	10,810	11,289
<b>Total equity and liabilities</b>	<b>100,669</b>	<b>42,792</b>	<b>49,043</b>

## Changes in equity

(SEK 000s)	<u>June 30</u> 2020	<u>June 30</u> 2019	<u>Dec. 31</u> 2019
Opening balance	35,620	26,071	26,071
Rights issue	49,572	0	0
Exchange rate difference	-1,513	53	-2
Profit/loss for the period	-3,528	2,918	9,551
<b>Amount at end of period</b>	<b>80,151</b>	<b>29,042</b>	<b>35,620</b>
Attributable to shareholders in Genovis AB	80,151	29,042	35,620
<b>Key financial figures</b>			
Equity/assets ratio (%)	81	68	73
Equity per share at end of period* (SEK)	1.22	0.46	0.56

\* Based on weighted average of the number of outstanding shares (basic and diluted).

## Summary Statement of Cash Flows

(SEK 000s)	<u>Q2</u>		<u>H1</u>		<u>Full year</u>
	2020	2019	2020	2019	2019
<b>Profit/loss for the period</b>	<b>-1,291</b>	<b>1,628</b>	<b>-3,180</b>	<b>3,571</b>	<b>10,067</b>
Adjustment for items not affecting cash flow	1,253	762	2,295	1,515	6,953
Change in working capital	205	-2,135	-383	-2,011	-3,496
Net financial items	-290	-110	-361	-220	-399
<b>Cash flow from operating activities</b>	<b>-123</b>	<b>145</b>	<b>-1,629</b>	<b>2,855</b>	<b>13,125</b>
Investing activities	-15,758	-1,708	-16,499	-2,434	-5,154
<b>Cash flow after investing activities</b>	<b>-15,881</b>	<b>-1,563</b>	<b>-18,128</b>	<b>421</b>	<b>7,971</b>
Financing activities	902	-540	118	-1,081	-2,560
Rights issue	-108	0	49,572	0	0
<b>Cash flow for the period</b>	<b>-15,087</b>	<b>-2,103</b>	<b>31,562</b>	<b>-660</b>	<b>5,411</b>
Cash and cash equivalents at start of period	61,641	11,024	14,992	9,581	9,581
<b>Cash and cash equivalents at close of period</b>	<b>46,554</b>	<b>8,921</b>	<b>46,554</b>	<b>8,921</b>	<b>14,992</b>

## Financial information – Parent Company

### Summary Income Statement

(SEK 000s)	<u>Q2</u>		<u>H1</u>		<u>Full year</u>
	2020	2019	2020	2019	2019
Operating income incl. change in inventory, finished goods	9,577	10,210	19,189	19,278	53,332
Operating expenses	-9,192	-9,184	-20,909	-17,317	-44,112
<b>Operating profit/loss</b>	<b>385</b>	1,026	<b>-1,720</b>	<b>1,961</b>	<b>9,220</b>
Net financial items	-215	-1	-216	-1	-2
<b>Profit/loss for the period</b>	<b>170</b>	1,025	<b>-1,936</b>	<b>1,960</b>	<b>9,218</b>

### Summary Balance Sheet

(SEK 000s)	<u>June 30</u>	<u>June 30</u>	<u>Dec. 31</u>
	2020	2019	2019
<b>Assets</b>			
Noncurrent assets	30,497	7,758	9,962
Current assets	21,617	20,938	18,573
Cash and cash equivalents	42,590	7,075	13,681
<b>Total assets</b>	<b>94,704</b>	<b>35,771</b>	<b>42,216</b>

(SEK 000s)	<u>June 30</u>	<u>June 30</u>	<u>Dec. 31</u>
	2020	2019	2019
<b>Equity and liabilities</b>			
Restricted equity	16,366	15,775	15,775
Unrestricted equity	65,923	11,621	18,879
<b>Liabilities</b>			
Current liabilities	12,415	8,375	7,562
<b>Total equity and liabilities</b>	<b>94,704</b>	<b>35,771</b>	<b>42,216</b>

### Changes in equity

(SEK 000s)	<u>June 30</u>	<u>June 30</u>	<u>Dec. 31</u>
	2020	2019	2019
Opening balance	34,654	25,436	25,436
Rights issue	49,571	0	0
Profit/loss for the period	-1,936	1,960	9,218
<b>Equity at the end of the period</b>	<b>82,289</b>	<b>27,396</b>	<b>34,654</b>
Attributable to shareholders in Genovis AB	82,289	27,396	34,654

## Summary Statement of Cash Flows

(SEK 000s)	Q2		H1		Full year
	2020	2019	2020	2019	2019
Profit/loss for the period	<b>385</b>	<b>1,018</b>	<b>-1,720</b>	<b>1,961</b>	<b>9,219</b>
Adjustment for items not affecting cash flow	312	202	608	395	4,369
Change in working capital	2,511	-1,608	1,808	-1,443	-3,348
Net financial items	-216	-1	-216	-1	-2
<b>Cash flow from operating activities</b>	<b>2,992</b>	<b>-389</b>	<b>480</b>	<b>912</b>	<b>10,238</b>
Investing activities	-20,401	-1,708	-21,143	-2,434	-5,154
<b>Cash flow after investing activities</b>	<b>-17,409</b>	<b>-2,097</b>	<b>-20,663</b>	<b>-1,522</b>	<b>5,084</b>
Financing activities	-108	0	49,572	0	0
<b>Cash flow for the period</b>	<b>-17,517</b>	<b>-2,097</b>	<b>28,909</b>	<b>-1,522</b>	<b>5,084</b>
Cash and cash equivalents at start of period	60,107	9,172	13,681	8,597	8,597
<b>Cash and cash equivalents at close of period</b>	<b>42,590</b>	<b>7,075</b>	<b>42,590</b>	<b>7,075</b>	<b>13,681</b>

### Statement by the Board of Directors and Chief Executive Officer

The Board of Directors and the Chief Executive Officer certify that this interim report provides a true and fair overview of the development of the Parent Company's and the Group's business activities, financial position and results of operations as well as the significant risks and uncertainties to which the Parent Company and the companies included in the Group are exposed.

Lund August 13, 2020  
Genovis AB (publ.)

On behalf of the Board of Directors Fredrik Olsson  
Chief Executive Officer

*This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on August 13, 2020.*

*This information is also available in Swedish. Please visit: <https://investor.genovis.com/en/>*